Cytel Releases Audiobook on Synthetic Control Arms (SCA)
Synthetic control arms (SCA) are virtual trial arms using observational data and historical claims data to simulate a study’s control [...]
What’s the Bottom Line? COVID-19 and Value-based Contracts
According to a new report released by Xtelligent Healthcare Media, the COVID-19 pandemic will shift the industry even farther away [...]
[Podcast] K&L Gates Triage: Rutledge v. Pharmaceutical Care Management Association
In this podcast, Leah D’Aurora Richardson and Victoria Hamscho discuss upcoming oral arguments to be heard before the Supreme Court [...]
COVID Test Costs Reach as High as $14,750
COVID-19 relief legislation that lets providers in some cases set their own prices for COVID diagnostic tests has resulted in [...]
[Webinar] Value Assessment in the Age of COVID-19
ISPOR, the Innovation and Value Initiative (IVI), and a panel of distinguished experts collaborate in this webinar series to define [...]
Industry Balks at Favored Nations Order
After talks broke down with the pharmaceutical industry's major lobby, PhRMA, the White House announced its plan to move ahead [...]
iHEA Accepting Abstract submissions for 2021 Congress
iHEA is pleased to invite you to join us virtually in July 2021 for the 14th World Congress on Health [...]
[Podcast] What Are the Implications of Teladoc’s Acquisition of Livongo?
Join Bob Matthews and Dan O’Neill as they discuss how the Teledoc and Livongo merger will result in a consumer-centric, [...]
[Conference] Health Technology Assessment: Challenges and Lessons Learned in Asia
Health technology assessment (HTA) has historically been easier and more impactful from a decision-maker or single payer perspective. However, many [...]
Using Real-world Data to Replicate Randomized Clinical Trial Results
The FDA intends to issue guidance on using real-world evidence (RWE) to aid in decisions about product effectiveness. Currently, there [...]
Trump Card: New Executive Order to Lower U.S. Drug Prices
Acting on a campaign promise to lower prescription drug prices, President Trump signed an executive order on Sunday aiming to [...]
New Guide Explains Role of Regulatory Medical Writers
Regulatory writing is a specialist type of writing that supports the drug approval and development process. The role of the [...]
The QALY and Value Assessment Frameworks in the Asia-Pacific Context
Although the QALY (quality-adjusted life year) has been a useful metric over the past few decades, it is not without [...]
Call for Proposals: AMCP 2021
AMCP is inviting proposals for continuing pharmacy education (CPE) sessions to be presented at AMCP 2021 on April 13-16, 2021 [...]
Towards a More Human-centered Approach to Improving Care: the Chief Outcomes Officer
COVID-19 has underscored the need to take a proactive, holistic approach to patient needs. Yet few health care organizations feel [...]
[Webinar] What Factors Determine Drug Prices?
What are all the different factors that impact what a patient pays at the pharmacy counter? Join Dr. Robert Popovian, [...]
ICER’s Hall of Shame: The Ten Least Cost-Effective Drugs
Read more here.
MDIC Releases Best Practices for Communicating Benefit, Risk, and Uncertainty for Medical Devices
The Medical Device Innovation Consortium (MDIC) released its report on of Best Practices for Communicating Benefit, Risk, and Uncertainty for [...]
How Medical Affairs Led Medical Education Benefits Patients
New article from the Medical Affairs Professional Society (MAPS) series, ELEVATE, details how patient outcomes are being optimized by Medical [...]
Benefits–Not Just Costs–of Medicines Must Be a Part of Discussion
According to Dr. Robert W. Dubois, Interim President and CEO of NPC, in the context of healthcare costs, the amount [...]
New Study Examines Perspective and Costing in Cost-Effectiveness Analysis
A recent study examined perspective and costing approaches used in cost-effectiveness analyses (CEAs) and the distribution of reported incremental cost-effectiveness [...]
Balancing Research Needs and Big Data Security in Europe
Optimal allocation of limited resources depends upon development of sound evidence demonstrating ‘value for money’ and is thus a critical [...]
HTA in the USA: ICER vs NICE
The Institute for Clinical and Economic Review (ICER) has a reputation for performing high-quality independent health technology assessments (HTAs) in [...]
Big Pharma’s Stealthy Efforts to Undermine ICER
The Institute for Clinical and Economic Review (ICER) wields considerable influence over drug prices by providing analysis of a medicine’s [...]
World’s Most Expensive Prescription Drug Shows Promise in Trial
Episalvan, an orphan drug for a condition called epidermolysis bullosa, is an EMA-approved drug for partial thickness wounds. Shortly after [...]